Table 1. Summary of different treatments and outcomes in patients with OC based on BRCA mutation status.

References	No. of patients	Type of OC	Treatment	BRCA mutation status	PFS	OS
Adams SF et al, 2011 [58]	23	EOC	(PLD) Doxil	BRCA 1/2 positive versus sporadic OC	27.1 weeks versus 17 weeks	89.1 weeks versus 48.3 weeks
Ledermann JA et al, 2012 [59]; Ledermann JA et al, 2014 [60] (Aka Study 19- basis for BRAC Analysis approval)	254	PSR HGSOC	Olaparib maintenance therapy versus placebo	BRCA 1/2 positive	11.2 months versus 4.1 months	No difference reported
Oza AM et al, 2015 [61]	107	PSR HGSOC	Paclitaxel + carboplatin versus paclitaxel + carboplatin + olaparib maintenance	BRCA 1/2 positive versus BRCA 1/2 negative	9.6 versus 12.2 months	Not reported
Louroso D et al, 2016 [11]	100	PSR OC versus PRR OC	Trabectedin	BRCA 1/2 positive or BRCAness versus unreported	No difference w.r.t. BRCA status	No difference w.r.t. BRCA status
Monk BJ et al, 2015 [62]	41	PRR OC	Trabectedin + PLD versus PLD	BRCA 1/2 positive	13.5 versus 5.5 months	23.8 versus 12.5 months
Liu JF et al, 2014 [63]	90	PSR HGSOC	Olaparib + cediranib versus olaparib	Mixed: BRCA positive + unknown	17.7 versus 9 months	Not reported

OC: Ovarian Cancer; BRCA: Breast cancer, early onset; PFS: Progression free survival; OS: Overall Survival; EOC: Epithelial OC; PSR HGSOC: Platinum Sensitive Recurrent High Grade Serous OC; PRR OC: Platinum resistant/refractory OC; PLD: Pegylated liposomal doxorubicin.